abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

这页面没有简体中文版本,现以English显示

文章

2005年8月13日

作者:
M G Arun, Financial Express [India]

Interview: Harvey E. Bale [Director General, International Federation of Pharmaceutical Manufacturers & Associations] - Patents, access to drugs is the issue

All countries have patent safeguards and have the right and ability to implement compulsory licensing in emergency circumstances...It is important for India and the rest of the world to have a good balance between implementation of innovation policies and those that give better access to medicine. There is no conflict between a patent system and the public’s access to medicines. [refers to Dr Reddy’s, Ranbaxy]